Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units (AMOCEF)

This study is currently recruiting participants.
Verified February 2013 by University Hospital, Ghent
Sponsor:
Information provided by (Responsible Party):
University Hospital, Ghent
ClinicalTrials.gov Identifier:
NCT01581047
First received: February 15, 2012
Last updated: February 1, 2013
Last verified: February 2013

February 15, 2012
February 1, 2013
March 2012
May 2013   (final data collection date for primary outcome measure)
  • Area under the serum concentration versus time curve (AUC) of Amoxicillin/Clavulanic acid. [ Time Frame: Before and at 15, 30, 45, 60, 120, 240 and 360 minutes after administration ] [ Designated as safety issue: No ]
    The concentrations of the antibiotic in serum samples, drawn at various times after one administration, will be measured. With these data, we can calculate the time above the minimal inhibitory concentration (MIC).
  • Area under the serum concentration versus time curve (AUC) of Cefuroxime. [ Time Frame: Before and at 15, 30, 45, 60, 120, 240 and 480 minutes after administration ] [ Designated as safety issue: No ]
    The concentrations of the antibiotic in serum samples, drawn at various times after one administration, will be measured. With these data, we can calculate the time above the minimal inhibitory concentration (MIC).
Same as current
Complete list of historical versions of study NCT01581047 on ClinicalTrials.gov Archive Site
  • Severity of disease classification. [ Time Frame: At date of admission (day 1) and dismissal (up to 3 months). ] [ Designated as safety issue: No ]
    This will be assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE2)-score.
  • Rate of organ failure. [ Time Frame: At date of admission (day 1) and dismissal (up to 3 months). ] [ Designated as safety issue: No ]
    This will be assessed using the Sequential Organ Failure Assessment score (SOFA-score).
  • Concentration serum creatinin [ Time Frame: At day 1. ] [ Designated as safety issue: No ]
  • 24 hour urine creatinine clearance [ Time Frame: At 24 hours ] [ Designated as safety issue: No ]
    Urine will be collected during 24 hours to measure the urine creatinine clearance.
  • Change in fluid balance [ Time Frame: From 0 to 24 hours. ] [ Designated as safety issue: No ]
    Change in fluid balance will be measured.
  • Concentration serum albumin [ Time Frame: At day 1. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units
Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units

Adequate antibiotic therapy is very important in the treatment of infections. Spectrum and dosing of the antibiotics are two factors of the therapy: the spectrum of an antibiotic can't be changed, but the dosing scheme can be optimized. Recent studies proved that an optimized dosing scheme can improve the efficacy of the treatment. Broad-spectrum antibiotics have unpredictable pharmacokinetics in patients on intensive care units. This is due to the pathophysiologic processes in the patients on intensive care units: increased distribution volume, hypoproteinemia, organ failure… The investigators guess that similar processes influence the pharmacokinetics of small spectrum antibiotics (like amoxicillin and cefuroxime), but data lacks. Because the pharmacokinetics of broad spectrum antibiotics in seriously ill patients are better known, physicians are more confident prescribing these drugs. Studying the pharmacokinetic interactions of small spectrum antibiotics in seriously ill patients, can help to give the physician the confidence to prescribe these small-spectrum antibiotics.

In this study, the investigators will study the pharmacokinetics of amoxicillin/clavulanic acid and cefuroxime, in 60 patients on intensive care. 8 blood samples will be drawn via a central catheter on different moments after one administration of the antibiotic in the steady state phase. All the patients are prescribed the antibiotics for the treatment of their infections: they get the antibiotic therapy anyway. By measuring the concentrations on different moments after one administration, the investigators can reconstruct the pharmacokinetic function.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

8 serum samples will be taken per patient.

Non-Probability Sample

Patients on the intensive care unit, with an infection (which requires amoxicillin/clavulanic acid or cefuroxime).

Infection
Not Provided
  • Amoxicillin/Clavulanic Acid
    Patients in the intensive care unit, with an infection which will be treated with Amoxicillin/Clavulanic Acid.
  • Cefuroxime
    Patients in the intensive care unit, with an infection which will be treated with Cefuroxime.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
June 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients on the intensive care unit, who are treated with amoxicillin/clavulanic acid or cefuroxime for an infection

Exclusion Criteria:

  • informed consent lacking
  • haematocrit < 21 %
  • arterial catheter lacking
Both
18 Years and older
No
Contact: Jan De Waele, MD, PhD Jan.DeWaele@ugent.be
Belgium
 
NCT01581047
2012/078, 2011-006107-35
No
University Hospital, Ghent
University Hospital, Ghent
Not Provided
Principal Investigator: Jan De Waele, MD, PhD Ghent University Hospital
University Hospital, Ghent
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP